Carbenoxolone disodium suppresses the migration of gastric cancer by targeting HDAC6

被引：6
|
作者：
Song, Zhiyu [1 ,2 ]
Zhao, Chenglong [1 ,2 ]
Yan, Jingjing [1 ,2 ]
Jiang, Dandan [1 ,2 ]
Jia, Gang [2 ,3 ]
机构：
[1] Henan Prov Peoples Hosp, Dept Pharm, Zhengzhou 450003, Henan, Peoples R China
[2] Zhengzhou Univ, Peoples Hosp, Zhengzhou 450003, Henan, Peoples R China
[3] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou 450003, Henan, Peoples R China
来源：
FUTURE MEDICINAL CHEMISTRY | 2023年 / 15卷 / 04期
基金：
中国国家自然科学基金;
关键词：
carbenoxolone disodium; gastric cancer; HDAC6; migration;
D O I：
10.4155/fmc-2022-0246
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Aim: Because of the severe morbidity and mortality of gastric cancer, discovering new candidate drugs has been an urgent issue. The close association between histone deacetylase 6 (HDAC6) and gastric cancer makes the development of HDAC6-targeted anti-gastric cancer drugs a viable idea. Methods & results: Carbenoxolone disodium was identified as a novel HDAC6 inhibitor. Cellular thermal shift assay, surface plasmon resonance assay and molecular docking confirmed its binding ability to HDAC6. Cell viability, wound healing and transwell assays as well as animal studies have demonstrated that carbenoxolone disodium could block the proliferation and migration of gastric cancer cells MGC-803 in vitro and in vivo. Conclusion: This is the first report to indicate that carbenoxolone disodium could be an HDAC6 inhibitor with potential for treatment of gastric cancer.
引用
收藏
页码：333 / 344
页数：12
相关论文
共 50 条
  • [1] SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6
    Zhang, Shi-Lan
    Du, Xiao
    Tan, Lin-Na
    Deng, Fei-Hong
    Zhou, Bing-Yi
    Zhou, He-Jun
    Zhu, Hong-Yi
    Chu, Yi
    Liu, De-Liang
    Tan, Yu-Yong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (02): : 602 - 611
  • [2] HDAC6 modulates colon cancer cell migration and invasion
    Li, Hui
    CANCER RESEARCH, 2020, 80 (16)
  • [3] The Role of HDAC6 in Cancer
    Aldana-Masangkay, Grace I.
    Sakamoto, Kathleen M.
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
  • [4] HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin
    Zuo, Qinqin
    Wu, Wenjing
    Li, Xu
    Zhao, Le
    Chen, Wei
    ONCOLOGY REPORTS, 2012, 27 (03) : 819 - 824
  • [5] HDAC6 and Ovarian Cancer
    Haakenson, Joshua
    Zhang, Xiaohong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (05) : 9514 - 9535
  • [6] Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
    Gu, Zhicheng
    Lin, Shuxian
    Yu, Junhui
    Jin, Fei
    Zhang, Qingqing
    Xia, Keli
    Chen, Lei
    Li, Yan
    He, Bin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 275
  • [7] Targeting HDAC6 to reduce the aggressiveness of metastatic breast cancer in immunotherapy
    Banik, Debarati
    Hadley, Melissa
    Palmer, Erica
    Gallub, Vincent
    Sotomayor, Eduardo
    Kozikowski, Alan
    Villagra, Alejandro
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Canagliflozin, characterized as a HDAC6 inhibitor, inhibits gastric cancer metastasis
    Jiang, Dandan
    Ma, Peizhi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] RASSF1A Suppresses Cell Migration through Inactivation of HDAC6 and Increase of Acetylated α-Tubulin
    Jung, Hae-Yun
    Jung, Jun Seok
    Whang, Young Mi
    Kim, Yeul Hong
    CANCER RESEARCH AND TREATMENT, 2013, 45 (02): : 134 - 144
  • [10] HDAC6: A unique HDAC family member as a cancer target
    Sumeet Kaur
    Prerna Rajoria
    Madhu Chopra
    Cellular Oncology, 2022, 45 : 779 - 829
12345